Haoxi Health Technology Ltd. (HAO) - Form 20-F Summary
Business Context and Reporting Period
Company: Haoxi Health Technology Ltd. (Cayman Islands holding company)
Operating Entity: Beijing Haoxi Digital Technology Co., Ltd. (PRC)
Reporting Period: Fiscal year ended June 30, 2024 (FY2024)
Business Model: Online marketing solution provider in China, specializing in short video ads for the healthcare industry. The company acts as an intermediary between advertisers and media platforms (primarily ByteDance/Ocean Engine).
Listing Status: Listed on Nasdaq Capital Market (Symbol: HAO) since January 26, 2024.
Key Financial Metrics (FY2024 vs. FY2023)
| Metric (USD) | FY2024 | FY2023 | Change |
|---|---|---|---|
| Revenue | $48.52 million | $28.23 million | +72% |
| Cost of Revenue | $45.77 million | $26.17 million | +75% |
| Gross Profit | $2.75 million | $2.06 million | +33% |
| Gross Margin | 5.7% | 7.3% | -1.6 pp |
| Net Income | $1.29 million | $0.97 million | +33% |
| Net Margin | 2.7% | 3.4% | -0.7 pp |
| Operating Cash Flow | ($0.75 million) | ($0.87 million) | Improvement |
| Cash & Equivalents (End of Period) | $6.66 million | $1.20 million | +455% |
| Total Debt (Short + Long Term) | $1.14 million | $0.76 million | +50% |
Material Changes and Drivers
- Revenue Growth: Driven by a 38% increase in advertiser customers (543 in FY2024 vs. 393 in FY2023) and higher average revenue per customer ($89,355 vs. $71,830). Growth is attributed to increased healthcare advertising spend post-pandemic restrictions.
- Margin Compression: Gross margin declined from 7.3% to 5.7% due to rising costs of traffic acquisition from media partners, partially offset by rebates.
- Liquidity Surge: Cash position increased significantly due to the IPO (Jan 2024) and a Follow-on Offering (Sept 2024), raising gross proceeds of $11.04 million and $12.00 million, respectively.
- Supplier Concentration: Purchases from a single supplier, Ocean Engine (ByteDance subsidiary), accounted for 99.66% of total purchases in FY2024, up from 96% in FY2023.
Outlook, Risks, and Contingencies
- Internal Controls: Management identified material weaknesses in Internal Control over Financial Reporting (ICFR), citing a lack of staff experienced in U.S. GAAP and insufficient monitoring mechanisms. Remediation plans include hiring an experienced CFO and establishing an internal audit department.
- Regulatory Risks (China): Significant risks related to PRC regulations, including the Overseas Listing Trial Measures (CSRC filing requirements), cybersecurity reviews, and potential restrictions on foreign investment in the online marketing sector.
- Delisting Risk: Potential risk under the Holding Foreign Companies Accountable Act (HFCA) if the PCAOB cannot inspect the company's auditor, though the current auditor (Wei, Wei & Co., LLP) is currently subject to PCAOB inspections.
- Customer Concentration: While no single customer exceeded 10% of revenue in FY2024, the top five customers accounted for 21.06% of revenue. Loss of major healthcare clients could materially impact results.
- Dividend Policy: The company does not anticipate paying cash dividends in the foreseeable future, intending to retain earnings for expansion.
Investor Verification Checklist
- Supplier Dependency: Verify the stability of the contract with Ocean Engine (99.66% of purchases) and the terms of renewal.
- ICFR Remediation: Monitor progress on fixing material weaknesses in financial reporting and internal controls.
- Regulatory Compliance: Confirm ongoing compliance with CSRC filing requirements and PRC cybersecurity/data privacy laws.
- Cash Utilization: Track the deployment of IPO and Follow-on proceeds, specifically the planned $2 million investment in R&D for the "Bidding Compass" software.
- Customer Retention: Assess the churn rate of healthcare advertisers and the sustainability of the 38% increase in customer count.